These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25249258)

  • 1. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.
    Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA
    Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
    Naffouje SA; O'Donoghue C; Salti GI
    J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalation of socioeconomic disparities among patients with colorectal cancer receiving advanced surgical treatment.
    Tabrizian P; Overbey J; Carrasco-Avino G; Bagiella E; Labow DM; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1746-50. PubMed ID: 25388060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.
    Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
    Klos D; Riško J; Kriváčková D; Loveček M; Skalický P; Neoral Č; Melichar B; Mohelníková-Duchoňová B; Lemstrová R
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):607-612. PubMed ID: 31982207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Lyon TD; Turner Ii RM; Nikonow TN; Wang L; Uy J; Ramalingam L; Holtzman MP; Pingpank JF; Bartlett DL; Davies BJ
    J Surg Oncol; 2016 Feb; 113(2):218-22. PubMed ID: 26775909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
    Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
    J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
    Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
    Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
    Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
    Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.